Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex ...
Vertex a ‘core large-cap biotech holding,’ says JPMorgan
After Vertex President and CEO Reshma Kewalramani presented at the firm’s healthcare conference, JPMorgan analyst Jessica Fye notes that the ...
Vertex Pharmaceuticals: Strong Pipeline and Strategic Growth Propel ‘Buy’ Rating
J.P. Morgan analyst Jessica Fye has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...
AFP1d
Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor ...
Vertex Pharmaceuticals Incorporated (VRTX) CEO Reshma Kewalramani Hosts 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.
My 3 Highest-Conviction Growth Stocks to Buy in 2025
Amazon Few companies enjoy as strong of a competitive moat as Amazon (NASDAQ: AMZN). Actually, Amazon has multiple strong moats. There's a networking moat with the company's e-commerce platform ...
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor ...
lifesciencesweden.se5d
FDA approves new cystic fibrosis therapy
A new treatment for cystic fibrosis has been approved by the U.S. Food and Drug Administration (FDA).
MedCity News12d
FDA Wraps Up 2024 Handing Out Several Notable Regulatory Decisions
Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.
BioPharma Dive12d
FDA approves drugs from Vertex, Novo, Bristol Myers to wrap 2024
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested
Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip
The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain Rating Scale after 12 weeks of treatment. Suzetrigine led to a statistically ...